Interim Report for Q3 2026

IQM booked EUR 42.2 million of new orders in Q3 2026, bringing year-to-date order intake to EUR 52.9 million and backlog to EUR 102.5 million at September 30, up 52% from the start of the year. Q3 revenue rose 51% year over year to EUR 8.9 million, and the company reaffirmed FY 2026 guidance. IQM said it has sold 31 quantum computers globally, with 17 delivered and 17 in production.

Analysis

Order quality matters more than headline growth. The key near-term question is whether the backlog converts into accepted, revenue-generating systems on schedule—not whether bookings continue to rise. Q3 supplied roughly 80% of year-to-date order intake, making the result unusually dependent on one quarter’s contracting cadence; the company says the LUMI-IQ Halocene program led orders, but does not disclose its share, delivery schedule, or cancellation terms. That concentration raises the risk that future bookings normalize even as the backlog remains elevated.

Over the next 1–3 months, monitor delivery/acceptance milestones, backlog composition, and FY guidance details. The gap between quarterly revenue and backlog signals substantial potential demand, but also multi-period execution risk; cash is a buffer, not evidence of attractive unit economics. Over 6–18 months, successful deployments could validate a repeatable systems business and improve credibility with research and public-sector buyers. Conversely, delays, customization costs, or weak gross margins could turn backlog into working-capital and cash-consumption pressure. Established quantum-computing efforts at IBM and IonQ may benefit if buyers keep budgets active, while also intensifying competition for talent and customer deployments.

Contrarian: the market may treat backlog growth as a leading indicator of durable revenue, when it is still a measure of commitments whose timing and economics are undisclosed. No trade is warranted solely on this release; avoid chasing a positive opening reaction until conversion and margin evidence improves. Thesis weakens if delivery cadence accelerates without adverse guidance or cash-flow signals; it fails if backlog slips, FY guidance is cut, or reported revenue and margins do not track deployments.

Key Decisions for Investors

• Do not chase the headline; keep exposure neutral pending contract-level backlog disclosure, especially delivery timing, customer concentration, and cancellation/acceptance terms.
• Set an alert for the next report: compare deliveries and revenue conversion with backlog, and verify gross margin and operating cash use before treating bookings as earnings visibility.
• For a 1–3 month catalyst trade, wait for evidence of on-time acceptance and guidance delivery; reduce exposure if backlog contracts or FY guidance is cut. No price target is justified from the supplied data.
• Track IBM and IonQ as competitive read-throughs, but do not assume IQM’s bookings translate into sector-wide quantum-computing monetization.